The Early Detection Research Network, Great Lakes-New England Clinical,
Epidemiological and Validation Center (GLNE CVC) announces the availability of
serum, plasma and urine samples for the early detection for colon cancer and validation
Two prospective studies were used to collect samples to make this
reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and
Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical
trial to collect serum, plasma, urine, and common data elements on subjects undergoing
routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon
cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of
Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to
collect serum, plasma, urine, stool, and common data elements. In both protocols,
subjects were undergoing routine colonoscopy (or being seen in surgery clinic for
colorectal cancer) when the samples were collected. Samples were collected while the
target lesions were still in place in the colon. Subjects were either normal (without
adenomas or cancer), with pathologically confirmed adenomas or pathologically
confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included
known hepatitis C or HIV, ulcerative colitis, Crohns’s Disease or IBD, history of cancer
within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were
collected from 4 sites around North America.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March, 2017 in Tempe, AZ. More information about this meeting will be available soon.